Mesirow Institutional Investment Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
$14.4M Buy
302,148
+82,643
+38% +$4.24M 1.11% 37
2024
Q3
$12.6M Sell
219,505
-70,300
-24% -$4.03M 0.96% 62
2024
Q2
$15.2M Sell
289,805
-74,242
-20% -$3.26M 1.33% 21
2024
Q1
$14.8M Sell
364,047
-89,780
-20% -$3.37M 1.32% 26
2023
Q4
$16.8M Buy
453,827
+73,412
+19% +$2.76M 1.57% 9
2023
Q3
$14.5M Sell
380,415
-42,297
-10% -$1.73M 1.47% 10
2023
Q2
$15.2M Buy
422,712
+89,537
+27% +$3.05M 1.57% 5
2023
Q1
$12.7M Buy
+333,175
New +$15.6M 1.38% 7

Other funds holding HALO

Mesirow Institutional Investment Management's HALO Position: Q4 2024 in Review

Mesirow Institutional Investment Management increased its Halozyme (HALO) stake by 38% in Q4 2024, buying an estimated $4.24M and bringing the position to 302,148 shares worth $14.4M. The position accounts for 1.11% of the portfolio, ranked #37.

Mesirow Institutional Investment Management first reported a position in HALO in Q1 2023 and has held it in 8 quarters since. The position peaked at $16.8M in Q4 2023. 508 funds tracked by Wall St. Rank hold HALO as of Q4 2024.

  • Mesirow Institutional Investment Management held 302,148 shares of Halozyme worth $14.4M as of Q4 2024.
  • Mesirow Institutional Investment Management bought 82,643 Halozyme shares in Q4 2024, an estimated $4.24M.
  • Halozyme made up 1.11% of Mesirow Institutional Investment Management's portfolio in Q4 2024, its #37 holding.
  • Mesirow Institutional Investment Management first reported a position in Halozyme in Q1 2023 and has held it in 8 quarters since.
  • Mesirow Institutional Investment Management's Halozyme position peaked at $16.8M in Q4 2023.
  • 508 funds tracked by Wall St. Rank held Halozyme as of Q4 2024.

Based on Mesirow Institutional Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.